Inhibitor Therapeutics (INTI) Stock Price, News & Analysis

Company Overview

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

Key Stats

• Today's Range: $0.05 to $0.06
• 50-Day Range: $0.04 to $0.07
• 52-Week Range: $0.04 to $0.14
• Volume: 29,000 shs
• Average Volume: 39,523 shs
• Market Capitalization: $10.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Inhibitor Therapeutics Stock Analysis - MarketRank™

Inhibitor Therapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Inhibitor Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Inhibitor Therapeutics is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inhibitor Therapeutics is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inhibitor Therapeutics has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Inhibitor Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Inhibitor Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inhibitor Therapeutics has recently increased by 22.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibitor Therapeutics does not currently pay a dividend.

Dividend Growth

Inhibitor Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Inhibitor Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Inhibitor Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inhibitor Therapeutics has recently increased by 22.73%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.11

News Sentiment

Inhibitor Therapeutics has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Inhibitor Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inhibitor Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Inhibitor Therapeutics is held by insiders.

INTI Stock Analysis - Frequently Asked Questions

How have INTI shares performed this year?

Inhibitor Therapeutics' stock was trading at $0.0601 at the beginning of the year. Since then, INTI shares have decreased by 0.8% and is now trading at $0.0596.
View the best growth stocks for 2025 here.

How were Inhibitor Therapeutics' earnings last quarter?

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) issued its quarterly earnings results on Friday, March, 28th. The company reported ($0.01) earnings per share for the quarter.

How do I buy shares of Inhibitor Therapeutics?

Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inhibitor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibitor Therapeutics investors own include AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Bank of America (BAC).

Company Calendar

• Last Earnings: 3/28/2025
• Today: 4/28/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:INTI
• CIK: 1042418
• Web: www.inhibitortx.com
• Phone: (888) 841-6811
• Fax: 813-527-0500
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,030,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.65%
• Return on Assets: -40.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 144.77
• Quick Ratio: 144.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 1.99

Miscellaneous

• Outstanding Shares: 172,574,000
• Free Float: 164,344,000
• Market Cap: $10.29 million
• Optionable: Not Optionable
• Beta: -0.61